Targeted patient-centered intervention reduces nonadministration of pharmacologic prophylaxis
MONDAY, Nov. 19, 2018 (HealthDay News) — A patient-centered education bundle intervention can reduce nonadministration of venous thromboembolism (VTE) prophylaxis, according to a study published online Nov. 16 in JAMA Network Open.
Elliott R. Haut, M.D., Ph.D., from the Johns Hopkins University School of Medicine in Baltimore, and colleagues conducted a nonrandomized comparison trial involving 19,652 patient visits during which at least one dose of VTE prophylaxis was prescribed from April 11 through Dec. 31, 2015. Patients on four intervention units received a patient-centered education bundle if VTE prophylaxis medication was not administered; patients on 12 control units received no intervention.
The researchers found that from the preintervention to postintervention period, the conditional odds of VTE prophylaxis nonadministration decreased significantly on intervention units (9.1 versus 5.6 percent; odds ratio, 0.57; 95 percent confidence interval, 0.48 to 0.67) compared with no change on control units (13.6 versus 13.3 percent; odds ratio, 0.98; 95 percent confidence interval, 0.91 to 1.07; P < 0.001 for interaction). On intervention units, there was a significant decrease in the conditional odds of nonadministration due to patient refusal (5.9 versus 3.4 percent; odds ratio, 0.53; 95 percent confidence interval, 0.43 to 0.65) compared with no change on control units (8.7 versus 8.5 percent; odds ratio, 0.98; 95 percent confidence interval, 0.89 to 1.08; P < 0.001 for interaction).
“The concept behind this intervention shows promise well beyond the delivery of VTE prevention,” the authors write.
Several authors disclosed financial ties to the pharmaceutical and publishing industries; several authors disclosed giving expert witness testimony in various medical malpractice cases.
Drug Interactions Reducing Contraceptive Effectiveness Common in Epilepsy
Most Specialty Oral Anticancer Meds for Blood Cancers Are Initially Rejected by Insurers
1 in 3 With Lupus Take Supplements, Medications With Potential for Interactions
Holding DMARDs at Time of COVID-19 Vaccine Not Warranted in Those With Inflammatory Arthritis
Age-, Joint-Specific Ultrasound Reference Values Set for Healthy Joints
2013 to 2024 Saw Decrease in Benzodiazepine Prescribing
GLP-1 Receptor Agonists, SGLT-2is Slow Renal Function Decline in T2D With Albuminuria
Polypharmacy of Prescription Medications Increased for U.S. Older Adults